

## Data Sharing Statement

|                     |  |  |
|---------------------|--|--|
| <b>Article Info</b> | http://dx.doi.org/10.21037/atm-20-669  |  |
| <b>Item</b>         | <b>Question</b>  | <b>Authors' Response</b><br>(place "-" if not applicable)  |
| 1                   | Would you like to share data collected for your study to others?   | Yes  |
| 2                   | If not, would you like to share the reason for your decision?  | -  |
| 3                   | What data in particular will be shared?  | The data about lipid changes during and after DAA treatment  |
| 4                   | Any other documents will be share? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code. | -  |
| 5                   | When will data availability begin?   | From the publication date.   |
| 6                   | When will data availability end?   | One year within the publication date   |
| 7                   | To whom will you share the data?   | Hepatologists, Infectious Diseases and Internal Medicine Specialists   |
| 8                   | For what type of analysis or purpose?  | To evaluate increase of the Cardio Vascular risk in HCV infected patients cured by DAA treatment   |
| 9                   | How or where can the data/documents be obtained?   | Emails could be sent to the address below to obtain the shared data:<br><a href="mailto:domenico.iossa@unicampania.it">domenico.iossa@unicampania.it</a> |
| 10                  | Any other restrictions?  | We may balance the potential benefits and risks for each request and then provide the data that could be shared.   |